NCT07153367 - Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

December 1, 2027

Conditions

InfertilityInsemination

Interventions

DRUG

REKOVELLE (Follitropin Delta)

"Each patient will start the ovarian stimulation with a fixed dose of 3,66 mcg of Rekovelle ® on day 4 of the natural cycle (Stimulation day 1-S1). The stimulation period will last a maximum of 13 days.~Patients will be regularly evaluated to monitor the response to stimulation with ultrasound scan and blood sampling"

Trial Locations (5)

13008

Cabinet Dr Géraldine PORCU-Institut de Médecine de la Reproduction, Marseille

33520

Cabinet Dr Elodie Descat-Polyclinique Jean Villar, Bruges

34070

Cabinet Dr Nicolas Chevalier-Centre AMP Saint Roch, Montpellier

92200

Cabinet Dr Nathalie Massin- Hôpital Américain De Paris, Neuilly-sur-Seine

94000

Chi Creteil, Créteil